Tami Jane Daugherty, MD
Gastroenterology · Emeryville
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 13
- 2 carriers
- Offices
- 7
Offices
7 locations · Stanford Health Care · 3,152 clinicians in this group
Looking this up.
Hospitals listed: Carson Valley Health · Renown Regional Medical Center · Stanford Health Care · Stanford Health Care Tri-Valley. That is not proof they admit you there this week.
Plans that list them
13 plans · 2 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Daugherty’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
13 of 13 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence A74786 · Current
Licensed to practise in California · since 2001 · expires 2027-01-31 · Columbia University College of Physicians and Surgeons.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
4 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Carson Valley HealthGardnerville, NVCritical Access Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Barton Health, which runs 2 hospitals in 2 statesPatients rate it 5 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsNo measure marked better or worse than the national rate
- Renown Regional Medical CenterReno, NVAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Renown Health, which runs 3 hospitalsPatients rate it 3 of 5 · 69% would definitely recommend itOverall rating: 3 of 5 starsWorse than the national rate — Death rate among surgical inpatients with serious treatable complications: 231.33 (200.05 to 262.61) · 302 cases, Jul 2022 – Jun 2024Better than the national rate — Pressure ulcer rate: 0.14 (0 to 0.56) · 11,907 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.438, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.208, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.636, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.344, Oct 2024 – Sep 2025Better than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 7.9 (6.3 to 9.9) · 547 cases, Jan 2024 – Dec 2024
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
- Stanford Health Care Tri-ValleyPleasanton, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Stanford Health Care, which runs 3 hospitalsPatients rate it 3 of 5 · 74% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.178, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.237, Oct 2024 – Sep 2025
See every measure and the patient survey for Carson Valley Health
Behind the star rating — Deaths: 0 better, 4 the same, 0 worse of 4 measures. Readmissions: 0 better, 7 the same, 0 worse of 7 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Death rate for COPD patientsComplications and deaths | 9.5 · 48 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 13.4 · 71 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 17.3 · 95 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 13.3 · 32 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 5.1 · 485 cases | None | Jul 2024 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 21.7 · 79 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 1.5 · 78 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -5.8 · 98 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.7 · 107 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.7 (3.7 to 8.6) · 52 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 9.8 (6.8 to 13.8) · 52 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19 · 54 cases | None | Jul 2023 – Jun 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.1 (0.8 to 1.5) · 262 cases | No different | Jan 2024 – Dec 2024 |
What patients said (293 patients answered, 30% of those asked)
| Cleanliness | 5 |
| Nurse communication | 5 |
| Doctor communication | 4 |
| Communication about medicines | 5 |
| Discharge information | 5 |
| Overall hospital rating | 5 |
| Quietness | 4 |
| Recommend hospital | 5 |
| Room was "always" clean | 86% |
| Nurses "always" communicated well | 85% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 72% |
| Yes, staff "did" give patients this information | 91% |
| Yes, staff "did" give patients information about help after discharge | 91% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 81% |
| Doctors "always" treated them with courtesy and respect | 88% |
| Patients who gave a rating of "9" or "10" (high) | 82% |
| Staff "always" explained new medications | 84% |
| Nurses "always" explained things so they could understand | 81% |
| Nurses "always" listened carefully | 82% |
| Nurses "always" treated them with courtesy and respect | 93% |
| "Always" quiet at night | 62% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 60% |
| Yes, staff "did" give patients information about possible symptoms | 91% |
See every measure and the patient survey for Renown Regional Medical Center
Behind the star rating — Deaths: 0 better, 7 the same, 1 worse of 8 measures. Safety: 3 better, 4 the same, 0 worse of 7 measures. Readmissions: 1 better, 9 the same, 0 worse of 10 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 231.33 (200.05 to 262.61) · 302 cases | Worse | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.14 (0 to 0.56) · 11,907 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.438 | Better | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.208 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.636 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.344 | Better | Oct 2024 – Sep 2025 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 7.9 (6.3 to 9.9) · 547 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.14 (0.36 to 1.92) · 3,106 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.04 (0.81 to 1.27) | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.3 · 123 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 8.6 · 225 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11 · 592 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 12.9 · 734 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 15.4 · 585 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 11 · 683 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.4 · 6,021 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.27 (0.11 to 0.44) · 14,463 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.33 (0.16 to 0.5) · 14,984 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.71 (3.29 to 6.12) · 4,503 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 2.62 (1.22 to 4.02) · 1,605 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 3.24 (2.11 to 4.36) · 4,125 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 11.78 (7 to 16.56) · 1,560 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (2.2 to 8.2) · 1,551 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.53 (0.22 to 2.83) · 1,024 cases | No different | Jul 2022 – Jun 2024 |
| MRSA BacteremiaInfections | 0.531 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.725 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 12.9 · 668 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22.2 · 1,041 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -11.3 · 643 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 1.6 · 850 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -8.5 · 631 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.3 · 776 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 4.8 (3.6 to 6.5) · 547 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission for CABGUnplanned return visits | 10 · 107 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.1 · 354 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.3 (9.8 to 18.1) · 50 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.1 (0.8 to 1.3) · 948 cases | No different | Jan 2024 – Dec 2024 |
What patients said (849 patients answered, 24% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 2 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 65% |
| Nurses "always" communicated well | 74% |
| Doctors "always" communicated well | 72% |
| Staff "always" explained | 56% |
| Yes, staff "did" give patients this information | 83% |
| Yes, staff "did" give patients information about help after discharge | 80% |
| Doctors "always" explained things so they could understand | 66% |
| Doctors "always" listened carefully | 71% |
| Doctors "always" treated them with courtesy and respect | 80% |
| Patients who gave a rating of "9" or "10" (high) | 67% |
| Staff "always" explained new medications | 71% |
| Nurses "always" explained things so they could understand | 70% |
| Nurses "always" listened carefully | 69% |
| Nurses "always" treated them with courtesy and respect | 82% |
| "Always" quiet at night | 44% |
| "YES", patients would definitely recommend the hospital | 69% |
| Staff "always" explained possible side effects | 41% |
| Yes, staff "did" give patients information about possible symptoms | 86% |
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
See every measure and the patient survey for Stanford Health Care Tri-Valley
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 2 better, 7 the same, 0 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.178 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.237 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.79 (0 to 1.73) · 1,041 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.79 (0.5 to 1.08) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 145.81 (96.5 to 195.12) · 72 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.9 · 55 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 8.6 · 92 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.5 · 96 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.5 · 395 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 391 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.1 · 162 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3 · 1,736 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.16 (0 to 0.37) · 4,425 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.22 (0.02 to 0.41) · 4,771 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.45 (1.46 to 5.44) · 1,403 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.5 (0.05 to 2.94) · 645 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.81 (0.38 to 3.24) · 1,279 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 8.53 (3.2 to 13.85) · 639 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.15 (1.89 to 8.41) · 648 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.61 (0.14 to 3.07) · 370 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.16 (0 to 0.83) · 4,160 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4 · 74 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.369 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 1.112 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 13.1 · 110 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.1 · 437 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -5.8 · 94 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -19.3 · 456 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -0.3 · 402 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 15.8 · 358 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.8 (4.7 to 9.6) · 198 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10.1 (7.5 to 13.6) · 198 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.3 · 80 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.9 · 46 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.3 · 92 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.4 (9.6 to 16.2) · 1,532 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.8 to 1.2) · 929 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,268 patients answered, 26% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 65% |
| Nurses "always" communicated well | 77% |
| Doctors "always" communicated well | 79% |
| Staff "always" explained | 58% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 88% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 78% |
| Doctors "always" treated them with courtesy and respect | 86% |
| Patients who gave a rating of "9" or "10" (high) | 70% |
| Staff "always" explained new medications | 72% |
| Nurses "always" explained things so they could understand | 73% |
| Nurses "always" listened carefully | 74% |
| Nurses "always" treated them with courtesy and respect | 84% |
| "Always" quiet at night | 42% |
| "YES", patients would definitely recommend the hospital | 74% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 89% |
Original Medicare doctor bills
$40,492
Medicare paid this office $40,492 for 162 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 45 | $16,520 | $106 |
| Return visit (30+ min) | 46 | $9,559 | $117 |
| Return visit (30+ min) | 25 | $3,079 | $83 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 14 | $1,627 | $116 |
| Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 15 | $1,479 | $99 |
See all 7 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 45 | $16,520 | $106 |
| Return visit (30+ min) | 46 | $9,559 | $117 |
| Return visit (30+ min) | 25 | $3,079 | $83 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 14 | $1,627 | $116 |
| Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 15 | $1,479 | $99 |
| Hospital discharge day management, more than 30 minutes | 12 | $1,254 | $105 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 17 | $250 | $15 |
Procedures Medicare counted
| Colonoscopy | 1-10 | None |
| Upper gastrointestinal (GI) endoscopy for acid reflux | 15 | More than 47% of doctors who do this |
Who their Medicare patients are
162 Original Medicare patients in 2024. Average age 65 · Under 65 35% · Women 46% · Also on Medicaid 49% · Health risk score 3.84. Sicker patients than 9 in 10 peers; the typical gastroenterology clinician is at 1.42.
Conditions among them: High blood pressure 75% · Chronic kidney disease 55% · Diabetes 54% · Coronary heart disease 31% · Depression 30% · Heart failure 29% · Atrial fibrillation 23% · COPD 12% · Dementia 10% · Cancer 9% · Stroke 9%.
The office billed $213,994, Medicare allowed $51,346 and paid $40,492; for 402 services of 22 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 162 | 402 | 65 | 3.84 | $213,994 | $40,492 |
| 2023 | 178 | 436 | 68 | 3.41 | $231,026 | $45,536 |
| 2022 | 195 | 500 | 67 | 3.09 | $247,413 | $44,519 |
| 2021 | 194 | 464 | 67 | 3.02 | $251,369 | $44,860 |
| 2020 | 194 | 417 | 66 | 3.35 | $196,325 | $35,725 |
| 2019 | 189 | 372 | 66 | 3.28 | $158,321 | $31,960 |
| 2018 | 228 | 546 | 66 | 3.29 | $217,364 | $46,721 |
| 2017 | 234 | 644 | 66 | 3.20 | $228,582 | $50,618 |
| 2016 | 240 | 615 | 65 | 3.22 | $244,508 | $53,382 |
| 2015 | 251 | 686 | 65 | 3.29 | $226,693 | $57,274 |
| 2014 | 267 | 766 | 65 | 2.86 | $240,974 | $63,168 |
| 2013 | 253 | 721 | 64 | 2.61 | $231,727 | $57,850 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 6 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 55 | $24,940 | $109 |
| Return visit (30+ min) | 52 | $4,968 | $89 |
| Return visit (30+ min) | 32 | $3,130 | $76 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 17 | $2,719 | $160 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 18 | $2,152 | $120 |
| Hospital discharge day management, more than 30 minutes | 18 | $1,928 | $107 |
2022: 7 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 54 | $23,127 | $94 |
| Return visit (30+ min) | 54 | $6,157 | $74 |
| Return visit (30+ min) | 24 | $2,676 | $84 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 17 | $2,098 | $123 |
| Hospital discharge day management, more than 30 minutes | 14 | $1,473 | $98 |
| Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 14 | $1,427 | $102 |
| Short return visit (20+ min) | 12 | $544 | $36 |
2021: 5 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 49 | $17,647 | $94 |
| Return visit (30+ min) | 54 | $6,323 | $84 |
| Return visit (30+ min) | 39 | $4,754 | $82 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 25 | $3,252 | $125 |
| Hospital discharge day management, more than 30 minutes | 11 | $1,301 | $100 |
2020: 6 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 46 | $13,648 | $96 |
| Return visit (30+ min) | 55 | $4,658 | $64 |
| Return visit (30+ min) | 47 | $3,766 | $63 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 19 | $2,416 | $127 |
| Hospital discharge day management, more than 30 minutes | 17 | $2,130 | $101 |
| Short return visit (20+ min) | 11 | $392 | $36 |
2019: 6 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 37 | $9,147 | $94 |
| Return visit (30+ min) | 64 | $7,205 | $67 |
| Return visit (30+ min) | 40 | $3,879 | $71 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 13 | $1,729 | $123 |
| New patient visit (45+ min) | 13 | $1,586 | $122 |
| Hospital discharge day management, more than 30 minutes | 12 | $1,190 | $99 |
2018: 8 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 51 | $16,925 | $94 |
| Return visit (30+ min) | 93 | $11,183 | $66 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 20 | $2,439 | $122 |
| Return visit (30+ min) | 29 | $2,273 | $71 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 13 | $1,413 | $109 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 15 | $1,304 | $65 |
| Hospital discharge day management, more than 30 minutes | 13 | $1,284 | $99 |
| Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monito | 14 | $53 | $4 |
2017: 8 services
| Return visit (30+ min) | 129 | $19,016 | $66 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 37 | $14,489 | $93 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 27 | $2,591 | $65 |
| Biopsy of large bowel using a flexible endoscope | 12 | $1,709 | $142 |
| New patient visit (45+ min) | 12 | $1,325 | $110 |
| Hospital discharge day management, more than 30 minutes | 11 | $1,178 | $98 |
| Short return visit (20+ min) | 17 | $767 | $40 |
| Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monito | 20 | $91 | $5 |
2016: 8 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 51 | $21,666 | $93 |
| Return visit (30+ min) | 119 | $13,200 | $66 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 13 | $2,343 | $180 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 17 | $2,065 | $121 |
| Hospital discharge day management, more than 30 minutes | 13 | $1,750 | $97 |
| New patient visit (45+ min) | 13 | $1,500 | $115 |
| Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 13 | $1,242 | $96 |
| Short return visit (20+ min) | 24 | $1,003 | $39 |
2015: 6 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 64 | $23,444 | $92 |
| Return visit (30+ min) | 141 | $17,428 | $66 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 29 | $4,024 | $122 |
| New patient visit (45+ min) | 13 | $1,500 | $115 |
| Hospital discharge day management, more than 30 minutes | 13 | $1,467 | $98 |
| Short return visit (20+ min) | 28 | $1,455 | $44 |
2014: 8 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 68 | $25,455 | $92 |
| Return visit (30+ min) | 159 | $21,815 | $65 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 22 | $2,678 | $122 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 11 | $2,338 | $180 |
| New patient visit (45+ min) | 19 | $2,197 | $116 |
| Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 11 | $1,316 | $110 |
| Short return visit (20+ min) | 19 | $845 | $42 |
| Return visit (30+ min) | 11 | $636 | $42 |
2013: 6 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 60 | $21,113 | $90 |
| Return visit (30+ min) | 159 | $20,589 | $61 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 33 | $4,059 | $116 |
| New patient visit (45+ min) | 17 | $1,534 | $90 |
| Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 12 | $1,294 | $108 |
| Short return visit (20+ min) | 23 | $1,101 | $42 |
Medicaid work
$7,742 in 2024
Medicaid paid $7,742 for 189 billed services this clinician did in 2024, up to 18 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Return visit (30+ min) | 77 | $4,473 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 112 | $3,269 |
| 2024 | 189 | 2 | 18 | $7,742 |
| 2023 | 402 | 3 | 24 | $14,790 |
| 2022 | 633 | 2 | 30 | $28,223 |
| 2021 | 360 | 2 | 17 | $13,057 |
| 2020 | 85 | 2 | 15 | $2,933 |
| 2019 | 58 | 1 | 14 | $1,932 |
| 2018 | 73 | 2 | 17 | $1,955 |
See the largest Medicaid services in earlier years
2023
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 282 | $9,718 |
| Return visit (30+ min) | 108 | $4,198 |
| Long return visit (40+ min) | 12 | $874 |
2022
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 497 | $21,956 |
| Return visit (30+ min) | 136 | $6,267 |
2021
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 285 | $10,105 |
| Return visit (30+ min) | 75 | $2,952 |
2020
| Return visit (30+ min) | 47 | $1,724 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 38 | $1,209 |
2019
| Return visit (30+ min) | 58 | $1,932 |
2018
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 56 | $1,529 |
| Return visit (30+ min) | 17 | $426 |
Drugs they prescribed that Part D paid
$419,925
Pharmacies billed $419,925 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
1,124 generic and fewer than 11 brand-name prescriptions · $419,925 in drug cost · 93 antibiotic prescriptions to 21 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Xifaxan | 63 | $208,078 | $3,303 |
| Vemlidy | 43 | $61,481 | $1,430 |
| Tacrolimus | 254 | $29,985 | $118 |
| Prograf | 16 | $20,429 | $1,277 |
| Entecavir | 68 | $17,982 | $264 |
See all 25 drugs
| Xifaxan | 63 | $208,078 | $3,303 |
| Vemlidy | 43 | $61,481 | $1,430 |
| Tacrolimus | 254 | $29,985 | $118 |
| Prograf | 16 | $20,429 | $1,277 |
| Entecavir | 68 | $17,982 | $264 |
| Cyclosporine | 20 | $8,277 | $414 |
| Ursodiol | 82 | $7,602 | $93 |
| Tenofovir Disoproxil | 39 | $5,972 | $153 |
| Mycophenolate Mofetil | 112 | $5,873 | $52 |
| Cyclosporine Modified | 40 | $5,621 | $141 |
| Sirolimus | 16 | $3,096 | $193 |
| Mycophenolic Acid | 17 | $2,358 | $139 |
| Lactulose | 30 | $709 | $24 |
| Pantoprazole | 74 | $539 | $7 |
| Mirtazapine | 19 | $303 | $16 |
| Furosemide | 34 | $287 | $8 |
| Gabapentin | 25 | $226 | $9 |
| Fludrocortisone Acetate | 16 | $216 | $13 |
| Amlodipine Besylate | 32 | $187 | $6 |
| Tamsulosin | 26 | $125 | $5 |
| Omeprazole | 16 | $120 | $7 |
| Prednisone | 11 | $109 | $10 |
| Carvedilol | 11 | $63 | $6 |
| Sulfamethoxazole-Trimethoprim | 14 | $28 | $2 |
| Glipizide | 13 | $9 | $1 |
Year by year
| 2024 | 1,291 | 123 | None | None | $419,925 |
| 2023 | 1,251 | 98 | None | 14% | $449,715 |
| 2022 | 1,390 | 117 | None | None | $537,529 |
| 2021 | 1,476 | 135 | None | None | $767,926 |
| 2020 | 1,355 | 141 | None | None | $624,934 |
| 2019 | 1,122 | 130 | None | 20% | $387,726 |
| 2018 | 1,207 | 154 | 1% (16) | None | $540,291 |
| 2017 | 1,360 | 145 | 1% (15) | None | $439,065 |
| 2016 | 1,359 | 152 | None | 28% | $1,791,513 |
| 2015 | 1,432 | 152 | None | None | $2,228,192 |
| 2014 | 1,541 | 138 | 1% (16) | 36% | $3,845,038 |
| 2013 | 1,270 | 106 | 1% (13) | 33% | $673,759 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 24 drugs
| Xifaxan | 51 | $170,466 | $3,342 |
| Vemlidy | 59 | $84,410 | $1,431 |
| Tacrolimus | 232 | $52,293 | $225 |
| Sirolimus | 20 | $17,711 | $886 |
| Entecavir | 75 | $14,032 | $187 |
| Mycophenolate Mofetil | 123 | $11,132 | $91 |
| Ursodiol | 66 | $10,355 | $157 |
| Cyclosporine | 22 | $9,537 | $433 |
| Cyclosporine Modified | 26 | $6,725 | $259 |
| Tenofovir Disoproxil | 22 | $5,151 | $234 |
| Lactulose | 58 | $1,970 | $34 |
| Pantoprazole | 69 | $867 | $13 |
| Amlodipine Besylate | 32 | $514 | $16 |
| Mirtazapine | 18 | $512 | $28 |
| Spironolactone | 14 | $440 | $31 |
| Atorvastatin | 12 | $270 | $23 |
| Fludrocortisone Acetate | 12 | $221 | $18 |
| Furosemide | 29 | $202 | $7 |
| Carvedilol | 13 | $178 | $14 |
| Prednisone | 26 | $175 | $7 |
| Amiloride | 14 | $98 | $7 |
| Gabapentin | 13 | $93 | $7 |
| Sulfamethoxazole-Trimethoprim | 15 | $50 | $3 |
| Glipizide | 12 | $44 | $4 |
2022: 30 drugs
| Xifaxan | 75 | $245,298 | $3,271 |
| Vemlidy | 64 | $86,327 | $1,349 |
| Tacrolimus | 206 | $40,933 | $199 |
| Ursodiol | 127 | $25,173 | $198 |
| Mycophenolate Mofetil | 115 | $11,307 | $98 |
| Cyclosporine | 22 | $9,413 | $428 |
| Atovaquone | 12 | $9,018 | $751 |
| Prograf | 12 | $7,681 | $640 |
| Cyclosporine Modified | 34 | $6,525 | $192 |
| Entecavir | 79 | $4,928 | $62 |
| Acyclovir | 11 | $2,920 | $265 |
| Lactulose | 43 | $2,781 | $65 |
| Tenofovir Disoproxil | 20 | $1,232 | $62 |
| Mycophenolic Acid | 12 | $1,010 | $84 |
| Azathioprine | 15 | $864 | $58 |
| Pantoprazole | 42 | $645 | $15 |
| Bumetanide | 11 | $614 | $56 |
| Gabapentin | 39 | $504 | $13 |
| Spironolactone | 22 | $494 | $22 |
| Hydrocortisone | 13 | $492 | $38 |
| Famotidine | 26 | $460 | $18 |
| Amlodipine Besylate | 23 | $325 | $14 |
| Fludrocortisone Acetate | 27 | $318 | $12 |
| Prednisone | 47 | $256 | $5 |
| Furosemide | 24 | $195 | $8 |
| Atorvastatin | 33 | $164 | $5 |
| Levothyroxine | 14 | $147 | $11 |
| Carvedilol | 11 | $106 | $10 |
| Metoprolol | 11 | $91 | $8 |
| Amiloride | 11 | $91 | $8 |
2021: 27 drugs
| Xifaxan | 72 | $211,498 | $2,937 |
| Promacta | 11 | $208,098 | $18,918 |
| Vemlidy | 90 | $114,290 | $1,270 |
| Tacrolimus | 193 | $41,675 | $216 |
| Ursodiol | 135 | $25,593 | $190 |
| Eliquis | 22 | $14,434 | $656 |
| Entecavir | 79 | $14,248 | $180 |
| Everolimus | 12 | $8,022 | $668 |
| Prograf | 12 | $7,093 | $591 |
| Cyclosporine Modified | 29 | $5,568 | $192 |
| Mycophenolate Mofetil | 73 | $4,851 | $66 |
| Lactulose | 52 | $3,099 | $60 |
| Mirtazapine | 34 | $1,423 | $42 |
| Tenofovir Disoproxil | 17 | $1,358 | $80 |
| Potassium Chloride | 22 | $1,161 | $53 |
| Azathioprine | 14 | $781 | $56 |
| Pantoprazole | 40 | $751 | $19 |
| Gabapentin | 32 | $480 | $15 |
| Spironolactone | 19 | $366 | $19 |
| Prednisone | 43 | $271 | $6 |
| Famotidine | 15 | $239 | $16 |
| Amlodipine Besylate | 29 | $203 | $7 |
| Fludrocortisone Acetate | 14 | $157 | $11 |
| Atorvastatin | 29 | $140 | $5 |
| Carvedilol | 16 | $116 | $7 |
| Sulfamethoxazole-Trimethoprim | 21 | $91 | $4 |
| Furosemide | 18 | $87 | $5 |
2020: 29 drugs
| Xifaxan | 65 | $207,101 | $3,186 |
| Vemlidy | 60 | $77,174 | $1,286 |
| Tacrolimus | 141 | $39,093 | $277 |
| Ursodiol | 135 | $37,385 | $277 |
| Entecavir | 100 | $16,058 | $161 |
| Eliquis | 28 | $13,520 | $483 |
| Prograf | 11 | $7,090 | $645 |
| Mycophenolate Mofetil | 76 | $3,505 | $46 |
| Cyclosporine Modified | 16 | $3,327 | $208 |
| Lactulose | 36 | $1,983 | $55 |
| Generlac | 21 | $1,949 | $93 |
| Mirtazapine | 40 | $1,472 | $37 |
| Pantoprazole | 51 | $917 | $18 |
| Potassium Chloride | 18 | $558 | $31 |
| Gabapentin | 21 | $421 | $20 |
| Famotidine | 19 | $370 | $19 |
| Spironolactone | 21 | $359 | $17 |
| Fludrocortisone Acetate | 17 | $278 | $16 |
| Furosemide | 44 | $249 | $6 |
| Prednisone | 41 | $202 | $5 |
| Amlodipine Besylate | 39 | $200 | $5 |
| Propranolol | 18 | $177 | $10 |
| Ropinirole | 11 | $169 | $15 |
| Levetiracetam | 11 | $161 | $15 |
| Metoprolol | 12 | $77 | $6 |
| Lisinopril | 23 | $63 | $3 |
| Tamsulosin | 12 | $62 | $5 |
| Quetiapine | 14 | $48 | $3 |
| Benazepril | 11 | $15 | $1 |
2019: 23 drugs
| Xifaxan | 46 | $144,759 | $3,147 |
| Vemlidy | 62 | $70,860 | $1,143 |
| Tacrolimus | 163 | $32,982 | $202 |
| Ursodiol | 94 | $25,791 | $274 |
| Entecavir | 107 | $17,001 | $159 |
| Mycophenolate Mofetil | 62 | $6,490 | $105 |
| Cyclosporine Modified | 22 | $5,320 | $242 |
| Lactulose | 29 | $1,627 | $56 |
| Pantoprazole | 51 | $579 | $11 |
| Gabapentin | 35 | $544 | $16 |
| Spironolactone | 29 | $393 | $14 |
| Ciprofloxacin | 12 | $239 | $20 |
| Levothyroxine | 16 | $186 | $12 |
| Omeprazole | 13 | $182 | $14 |
| Ropinirole | 13 | $167 | $13 |
| Prednisone | 22 | $164 | $7 |
| Fludrocortisone Acetate | 13 | $155 | $12 |
| Amlodipine Besylate | 30 | $147 | $5 |
| Propranolol | 14 | $138 | $10 |
| Furosemide | 22 | $128 | $6 |
| Metoprolol | 15 | $102 | $7 |
| Quetiapine | 12 | $47 | $4 |
| Atenolol | 12 | $28 | $2 |
2018: 31 drugs
| Xifaxan | 53 | $131,268 | $2,477 |
| Entecavir | 110 | $48,157 | $438 |
| Vemlidy | 29 | $32,536 | $1,122 |
| Ursodiol | 71 | $26,100 | $368 |
| Tacrolimus | 141 | $25,552 | $181 |
| Prograf | 18 | $14,225 | $790 |
| Creon | 13 | $12,784 | $983 |
| Tenofovir Disoproxil | 20 | $9,217 | $461 |
| Mycophenolate Mofetil | 57 | $8,706 | $153 |
| Cyclosporine Modified | 21 | $5,534 | $264 |
| Generlac | 24 | $1,537 | $64 |
| Gengraf | 12 | $1,139 | $95 |
| Pantoprazole | 64 | $840 | $13 |
| Mirtazapine | 12 | $771 | $64 |
| Levothyroxine | 43 | $674 | $16 |
| Lactulose | 11 | $626 | $57 |
| Spironolactone | 39 | $576 | $15 |
| Gabapentin | 29 | $435 | $15 |
| Potassium Chloride | 11 | $409 | $37 |
| Polyethylene Glycol 3350 | 12 | $343 | $29 |
| Doxepin | 14 | $321 | $23 |
| Loperamide | 13 | $279 | $21 |
| Propranolol | 18 | $270 | $15 |
| Fludrocortisone Acetate | 19 | $182 | $10 |
| Omeprazole | 16 | $146 | $9 |
| Prednisone | 21 | $135 | $6 |
| Ciprofloxacin | 13 | $129 | $10 |
| Ropinirole | 12 | $128 | $11 |
| Furosemide | 27 | $121 | $4 |
| Terazosin | 12 | $42 | $3 |
| Atenolol | 12 | $29 | $2 |
2017: 33 drugs
| Xifaxan | 35 | $82,029 | $2,344 |
| Entecavir | 104 | $55,213 | $531 |
| Viread | 29 | $31,090 | $1,072 |
| Ursodiol | 85 | $27,969 | $329 |
| Baraclude | 22 | $26,084 | $1,186 |
| Tacrolimus | 132 | $22,660 | $172 |
| Vemlidy | 12 | $12,544 | $1,045 |
| Prograf | 25 | $11,233 | $449 |
| Mycophenolate Mofetil | 73 | $10,185 | $140 |
| Cyclosporine | 20 | $5,592 | $280 |
| Cyclosporine Modified | 24 | $3,777 | $157 |
| Omega-3 Acid Ethyl Esters | 17 | $1,626 | $96 |
| Azathioprine | 18 | $1,278 | $71 |
| Gabapentin | 41 | $863 | $21 |
| Spironolactone | 66 | $690 | $10 |
| Pantoprazole | 59 | $555 | $9 |
| Levothyroxine | 34 | $494 | $15 |
| Mirtazapine | 31 | $491 | $16 |
| Prednisone | 47 | $395 | $8 |
| Polyethylene Glycol 3350 | 21 | $347 | $17 |
| Loperamide | 14 | $315 | $22 |
| Lactulose | 15 | $308 | $21 |
| Furosemide | 50 | $304 | $6 |
| Doxepin | 13 | $260 | $20 |
| Fludrocortisone Acetate | 20 | $254 | $13 |
| Omeprazole | 26 | $235 | $9 |
| Propranolol | 11 | $208 | $19 |
| Amlodipine Besylate | 32 | $187 | $6 |
| Ropinirole | 12 | $163 | $14 |
| Tramadol | 12 | $86 | $7 |
| Ciprofloxacin | 15 | $64 | $4 |
| Sulfamethoxazole-Trimethoprim | 13 | $63 | $5 |
| Atenolol | 12 | $19 | $2 |
2016: 34 drugs
| Harvoni | 20 | $624,954 | $31,248 |
| Epclusa | 13 | $323,998 | $24,923 |
| Viread | 63 | $61,401 | $975 |
| Entecavir | 76 | $56,407 | $742 |
| Xifaxan | 30 | $54,538 | $1,818 |
| Baraclude | 34 | $41,907 | $1,233 |
| Ursodiol | 64 | $27,345 | $427 |
| Tacrolimus | 180 | $25,776 | $143 |
| Atovaquone | 12 | $16,420 | $1,368 |
| Prograf | 27 | $11,514 | $426 |
| Mycophenolate Mofetil | 81 | $6,122 | $76 |
| Ampicillin | 17 | $3,075 | $181 |
| Ceftriaxone | 12 | $2,643 | $220 |
| Gabapentin | 31 | $1,968 | $63 |
| Omeprazole | 46 | $958 | $21 |
| Lactulose | 19 | $880 | $46 |
| Azathioprine | 13 | $832 | $64 |
| Ropinirole | 12 | $619 | $52 |
| Spironolactone | 34 | $571 | $17 |
| Pantoprazole | 48 | $566 | $12 |
| Fludrocortisone Acetate | 28 | $419 | $15 |
| Propranolol | 20 | $310 | $15 |
| Amlodipine Besylate | 49 | $280 | $6 |
| Mirtazapine | 22 | $261 | $12 |
| Prednisone | 38 | $261 | $7 |
| Amiloride | 12 | $251 | $21 |
| Levothyroxine | 24 | $220 | $9 |
| Constulose | 11 | $215 | $20 |
| Furosemide | 30 | $160 | $5 |
| Metoprolol | 11 | $91 | $8 |
| Glipizide | 13 | $88 | $7 |
| Warfarin | 13 | $81 | $6 |
| Olanzapine | 12 | $80 | $7 |
| Ciprofloxacin | 11 | $39 | $4 |
2015: 36 drugs
| Harvoni | 40 | $1,196,412 | $29,910 |
| Sovaldi | 13 | $367,072 | $28,236 |
| Nexavar | 12 | $117,772 | $9,814 |
| Entecavir | 106 | $98,168 | $926 |
| Xifaxan | 55 | $89,116 | $1,620 |
| Noxafil | 12 | $80,814 | $6,734 |
| Viread | 71 | $63,595 | $896 |
| Baraclude | 34 | $41,736 | $1,228 |
| Ursodiol | 84 | $34,066 | $406 |
| Tacrolimus | 136 | $27,545 | $203 |
| Prograf | 50 | $27,231 | $545 |
| Sandimmune | 16 | $7,301 | $456 |
| Mycophenolate Mofetil | 78 | $4,101 | $53 |
| Gengraf | 12 | $3,380 | $282 |
| Gabapentin | 21 | $2,381 | $113 |
| Ribasphere | 13 | $1,902 | $146 |
| Lactulose | 21 | $1,338 | $64 |
| Omeprazole | 74 | $1,207 | $16 |
| Ropinirole | 12 | $823 | $69 |
| Azathioprine | 12 | $807 | $67 |
| Spironolactone | 30 | $636 | $21 |
| Pantoprazole | 32 | $560 | $17 |
| Amiloride | 12 | $482 | $40 |
| Propranolol | 28 | $445 | $16 |
| Prednisone | 52 | $419 | $8 |
| Fludrocortisone Acetate | 28 | $390 | $14 |
| Metoprolol | 15 | $385 | $26 |
| Metoprolol | 38 | $299 | $8 |
| Levetiracetam | 12 | $293 | $24 |
| Amlodipine Besylate | 40 | $232 | $6 |
| Glipizide | 23 | $207 | $9 |
| Mirtazapine | 12 | $164 | $14 |
| Diphenoxylate-Atropine | 11 | $162 | $15 |
| Furosemide | 27 | $101 | $4 |
| Olanzapine | 13 | $83 | $6 |
| Ciprofloxacin | 21 | $81 | $4 |
2014: 35 drugs
| Sovaldi | 74 | $2,151,550 | $29,075 |
| Olysio | 38 | $855,664 | $22,517 |
| Nexavar | 15 | $166,076 | $11,072 |
| Xifaxan | 78 | $113,107 | $1,450 |
| Baraclude | 84 | $100,356 | $1,195 |
| Viread | 55 | $49,165 | $894 |
| Tacrolimus | 178 | $39,529 | $222 |
| Procrit | 11 | $36,293 | $3,299 |
| Prograf | 35 | $20,646 | $590 |
| Ursodiol | 106 | $19,854 | $187 |
| Entecavir | 15 | $15,284 | $1,019 |
| Ribavirin | 24 | $4,655 | $194 |
| Mycophenolate Mofetil | 57 | $4,646 | $82 |
| Gabapentin | 28 | $2,794 | $100 |
| Omeprazole | 65 | $1,254 | $19 |
| Lactulose | 19 | $679 | $36 |
| Ropinirole | 12 | $630 | $52 |
| Prednisone | 46 | $566 | $12 |
| Bd Ultra-Fine Pen Needle | 14 | $543 | $39 |
| Fludrocortisone Acetate | 27 | $465 | $17 |
| Spironolactone | 24 | $449 | $19 |
| Metoprolol | 13 | $409 | $31 |
| Mirtazapine | 13 | $328 | $25 |
| Pantoprazole | 24 | $248 | $10 |
| Amlodipine Besylate | 41 | $243 | $6 |
| Venlafaxine Hcl Er | 13 | $226 | $17 |
| Propranolol | 31 | $212 | $7 |
| Metoprolol | 22 | $183 | $8 |
| Doxepin | 13 | $166 | $13 |
| Glipizide | 16 | $163 | $10 |
| Famotidine | 11 | $135 | $12 |
| Diphenoxylate-Atropine | 11 | $127 | $12 |
| Ciprofloxacin | 17 | $98 | $6 |
| Furosemide | 24 | $94 | $4 |
| Sulfamethoxazole-Trimethoprim | 13 | $82 | $6 |
2013: 35 drugs
| Victrelis | 22 | $124,433 | $5,656 |
| Xifaxan | 68 | $97,729 | $1,437 |
| Pegasys | 32 | $91,663 | $2,864 |
| Baraclude | 62 | $64,309 | $1,037 |
| Procrit | 13 | $40,680 | $3,129 |
| Neupogen | 22 | $27,415 | $1,246 |
| Viread | 37 | $25,585 | $691 |
| Ribapak | 19 | $16,568 | $872 |
| Tacrolimus | 77 | $14,454 | $188 |
| Mycophenolate Mofetil | 78 | $8,419 | $108 |
| Cyclosporine Modified | 20 | $7,668 | $383 |
| Ursodiol | 79 | $6,929 | $88 |
| Ribasphere | 13 | $1,299 | $100 |
| Ropinirole | 17 | $1,097 | $65 |
| Omeprazole | 52 | $1,073 | $21 |
| Lactulose | 29 | $1,040 | $36 |
| Potassium Chloride | 27 | $766 | $28 |
| Azathioprine | 25 | $543 | $22 |
| Spironolactone | 20 | $494 | $25 |
| Cholestyramine | 13 | $476 | $37 |
| Bd Ultra-Fine Pen Needle | 12 | $434 | $36 |
| Metoprolol | 14 | $433 | $31 |
| Gabapentin | 20 | $326 | $16 |
| Furosemide | 53 | $204 | $4 |
| Amlodipine Besylate | 30 | $201 | $7 |
| Prednisone | 30 | $198 | $7 |
| Propranolol | 35 | $155 | $4 |
| Metoprolol | 17 | $154 | $9 |
| Loperamide | 12 | $153 | $13 |
| Famotidine | 17 | $126 | $7 |
| Citalopram Hbr | 20 | $117 | $6 |
| Doxepin | 13 | $115 | $9 |
| Pantoprazole | 12 | $105 | $9 |
| Ciprofloxacin | 21 | $84 | $4 |
| Levothyroxine | 12 | $74 | $6 |
Money from drug and device companies
$29 in 2025
| 2025 | 1 | 1 | None | $29 |
| 2024 | 2 | 2 | None | $156 |
| 2022 | 1 | 1 | None | $123 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Mauna Kea Technologies | None | $29 | 1 payment
|
See the published payment
| Mauna Kea Technologies | Meals · 2025-07-21 | None | $29 |
See earlier years (2024, 2022)
2024: $156
| Ethicon US | Stratafix | $140 | 1 payment
|
| Abbvie | Mavyret | $15 | 1 payment
|
2022: $123
| Gilead Sciences | None | $123 | 1 payment
|
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 76.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1194742064
- Licence
- CA A74786California A74786: Current · expires 2027-01-31
- Trained
- Columbia University College of Physicians and Surgeons, 1999
- Group
- Stanford Health Care
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207RT0003X (207RT0003X); Internal medicine (207R00000X); Federal specialty code 207RG0100X (207RG0100X)
- Mailing address
- 300 Pasteur Dr, Palo Alto, CA, 94304
- NPI first listed
- 2006-07-16
- NPI last updated
- 2026-09-02
- NPI record certified
- 2026-09-02
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 1500 E 2nd St Ste 300, Reno, NV, 89502